Hualan Biological Engineering Inc. (SZSE: 002007)
Health Care · Biotechnology · CN
CN¥13.35
+0.07% today · -18.0% 1Y
Hualan Biological Engineering Inc. (SZSE: 002007) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.64B and employs 4,117 people.
Over the last twelve months the share price has lost 18.0%, trading between 11.72 and 17.09.
Tweenvest scores Hualan Biological Engineering Inc. across four factors: quality 73/100, value 48/100, growth 19/100, dividend 31/100. Its strongest factor is quality.
002007 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.64B
- Revenue (TTM)
- $642.37M
- P/E
- 30.16
- EPS
- 0.44
- Dividend yield
- 3.00%
- Beta (5Y)
- 0.36
- 52-week high
- CN¥17.09
- 52-week low
- CN¥11.72
- Avg volume (3M)
- —
- Shares outstanding
- 1.83B
- Employees
- 4,117
- Next earnings
- —
About Hualan Biological Engineering Inc.
Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
- ISIN
- CNE000001JN8
- Founded
- 1992
- Listed since
- Jun 25, 2004
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tango Therapeutics, Inc.NasdaqGM: TNGX | $4.01B | $24.00 | +0.80% |
| Relay Therapeutics, Inc.NasdaqGM: RLAY | $3.92B | $17.92 | +0.22% |
| Telix Pharmaceuticals LimitedASX: TLX | $3.76B | AU$15.85 | -0.13% |
| Beijing Tiantan Biological Products Co., Ltd.SHSE: 600161 | $3.76B | CN¥12.73 | +1.11% |
| Veracyte, Inc.NasdaqGM: VCYT | $3.64B | $43.53 | -3.76% |
| Legend Biotech CorporationNasdaqGS: LEGN | $3.61B | $18.29 | -1.77% |
| Xenon Pharmaceuticals Inc.NasdaqGM: XENE | $3.53B | $36.00 | -1.21% |
| Shanghai Henlius Biotech, Inc.SEHK: 2696 | $3.53B | HK$50.75 | -13.10% |
Figures last refreshed Oct 11, 2026.